Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

201 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Diagnostic Performance of the Fibrosis-4 Index and Nonalcoholic Fatty Liver Disease Fibrosis Score in Lean Adults With Nonalcoholic Fatty Liver Disease.
Park H, Yoon EL, Ito T, Jo AJ, Kim M, Lee J, Kim HL, Arai T, Atsukawa M, Kawanaka M, Toyoda H, Ishigami M, Yu ML, Jun DW, Nguyen MH. Park H, et al. Among authors: atsukawa m. JAMA Netw Open. 2023 Aug 1;6(8):e2329568. doi: 10.1001/jamanetworkopen.2023.29568. JAMA Netw Open. 2023. PMID: 37589973 Free PMC article.
A 48-week telaprevir-based triple combination therapy improves sustained virological response rate in previous non-responders to peginterferon and ribavirin with genotype 1b chronic hepatitis C: A multicenter study.
Shimada N, Tsubota A, Atsukawa M, Abe H, Ide T, Takaguchi K, Chuganji Y, Toyoda H, Yoshizawa K, Ika M, Sato Y, Kato K, Kumada T, Sakamoto C, Aizawa Y, Sata M. Shimada N, et al. Among authors: atsukawa m. Hepatol Res. 2014 Dec;44(14):E386-96. doi: 10.1111/hepr.12323. Epub 2014 Apr 15. Hepatol Res. 2014. PMID: 24606109
Factors associated with sustained virological response in 24-week telaprevir-based triple therapy for chronic hepatitis C genotype 1b patients with the IL28B minor genotype.
Abe H, Tsubota A, Shimada N, Atsukawa M, Kato K, Takaguchi K, Asano T, Chuganji Y, Sakamoto C, Toyoda H, Kumada T, Ide T, Sata M, Aizawa Y. Abe H, et al. Among authors: atsukawa m. Hepatol Res. 2015 Apr;45(4):387-96. doi: 10.1111/hepr.12360. Epub 2014 Jul 18. Hepatol Res. 2015. PMID: 24849518
Interleukin-34 as a fibroblast-derived marker of liver fibrosis in patients with non-alcoholic fatty liver disease.
Shoji H, Yoshio S, Mano Y, Kumagai E, Sugiyama M, Korenaga M, Arai T, Itokawa N, Atsukawa M, Aikata H, Hyogo H, Chayama K, Ohashi T, Ito K, Yoneda M, Nozaki Y, Kawaguchi T, Torimura T, Abe M, Hiasa Y, Fukai M, Kamiyama T, Taketomi A, Mizokami M, Kanto T. Shoji H, et al. Among authors: atsukawa m. Sci Rep. 2016 Jul 1;6:28814. doi: 10.1038/srep28814. Sci Rep. 2016. PMID: 27363523 Free PMC article.
Serum YKL-40 as a marker of liver fibrosis in patients with non-alcoholic fatty liver disease.
Kumagai E, Mano Y, Yoshio S, Shoji H, Sugiyama M, Korenaga M, Ishida T, Arai T, Itokawa N, Atsukawa M, Hyogo H, Chayama K, Ohashi T, Ito K, Yoneda M, Kawaguchi T, Torimura T, Nozaki Y, Watanabe S, Mizokami M, Kanto T. Kumagai E, et al. Among authors: atsukawa m. Sci Rep. 2016 Oct 14;6:35282. doi: 10.1038/srep35282. Sci Rep. 2016. PMID: 27739482 Free PMC article.
Analysis of factors predicting the response to tolvaptan in patients with liver cirrhosis and hepatic edema.
Atsukawa M, Tsubota A, Kato K, Abe H, Shimada N, Asano T, Ikegami T, Koeda M, Okubo T, Arai T, Nakagawa-Iwashita A, Yoshida Y, Hayama K, Itokawa N, Kondo C, Chuganji Y, Matsuzaki Y, Iwakiri K. Atsukawa M, et al. J Gastroenterol Hepatol. 2018 Jun;33(6):1256-1263. doi: 10.1111/jgh.14047. Epub 2018 Feb 19. J Gastroenterol Hepatol. 2018. PMID: 29215154
Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein more reliably distinguishes liver fibrosis stages in non-alcoholic fatty liver disease than serum Mac-2 binding protein.
Atsukawa M, Tsubota A, Okubo T, Arai T, Nakagawa A, Itokawa N, Kondo C, Kato K, Hatori T, Hano H, Oikawa T, Emoto N, Abe M, Kage M, Iwakiri K. Atsukawa M, et al. Hepatol Res. 2018 May;48(6):424-432. doi: 10.1111/hepr.13046. Epub 2018 Jan 10. Hepatol Res. 2018. PMID: 29274190
Efficacy and safety of ombitasvir/paritaprevir/ritonavir combination therapy for genotype 1b chronic hepatitis C patients complicated with chronic kidney disease.
Arai T, Atsukawa M, Tsubota A, Ikegami T, Shimada N, Kato K, Abe H, Okubo T, Itokawa N, Kondo C, Mikami S, Asano T, Chuganji Y, Matsuzaki Y, Toyoda H, Kumada T, Iio E, Tanaka Y, Iwakiri K. Arai T, et al. Among authors: atsukawa m. Hepatol Res. 2018 Jun;48(7):549-555. doi: 10.1111/hepr.13058. Epub 2018 Feb 21. Hepatol Res. 2018. PMID: 29316062
Efficacy and safety of ledipasvir/sofosbuvir for genotype 1b chronic hepatitis C patients with moderate renal impairment.
Okubo T, Atsukawa M, Tsubota A, Toyoda H, Shimada N, Abe H, Kato K, Hayama K, Arai T, Nakagawa-Iwashita A, Itokawa N, Kondo C, Kawamoto C, Iio E, Tanaka Y, Kumada T, Iwakiri K. Okubo T, et al. Among authors: atsukawa m. Hepatol Int. 2018 Mar;12(2):133-142. doi: 10.1007/s12072-018-9859-9. Epub 2018 Mar 29. Hepatol Int. 2018. PMID: 29600429
201 results